Orchid Pharma share news, announcements and annual reports
NSE: ORCHPHARMABSE: 524372Pharmaceuticals & BiotechnologySmall Cap
Orchid Pharma Limited · Formerly Orchid Chemicals & Pharmaceuticals · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1993 on BSE, Jul 2007 on NSE
Last close ₹836.45down ₹56.95 (6.37%)BSE ₹833.05
Share price at the NSE close on 30 Oct 2026. Previous close ₹893.40.
30 Oct: open ₹893.45, high ₹893.45, low ₹830.00
52-week range of traded prices to 30 Oct 2026
₹480.00Low, 30 Mar 2026₹1,143.50High, 22 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹5,009 Cr919th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 0.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.19
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 88,12456.8% delivered
Orchid Pharma share news and announcements
856 announcements, routine notices left out, newest first. Page 16 of 18.
Aug 2009
13 Aug · Business
Media release dated August 13, 2009, titled "Orchid receives Final US FDA nod for Sumatriptan Tablets". A copy of the media release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Aug · Business
Media release dated August 12, 2009, titled "Orchid Chemicals & Pharmaceuticals Ltd (Orchid) and Schering-Plough Corporation (SGP) Settle Clarinex and Clarinex RediTabs Patent Lawsuits". A copy of the media release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2009
31 Jul · Business
Press release dated July 31, 2009 titled "Orchid registers turnover of Rs 309 crore during Q1 FY10". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.31 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 30581.89 lacs for quarter ending on 30-JUN-2009 against Rs. 28765.92 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. (2976.05) lacs for the quarter ending on 30-JUN-2009 against Rs. (3164.6) lacs for the quarter ending on 30-JUN-2008.21 Jul · Board meeting
To take on record the unaudited financial results of Orchid for the period from April 1, 2009 to June 30, 2009.3 Jul · Business
Press release dated July 03, 2009 titled "Orchid receives US FDA approval for Amlodipine Besylate Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2009
29 Jun · Business
Press release dated June 29, 2009, titled " Orchid registers a turnover of Rs. 1211 crore during FY09". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Jun · Dividend
Board of Directors of the Company at its meeting held on June 29, 2009 has recommended a dividend of Re. 1/- per share on the equity share of Rs.10/- each.29 Jun · Results
Standalone Results for the year ended on 31-MAR-2009 as follows: Net Sales of Rs. 115676.96 lacs for year ending on 31-MAR-2009 against Rs. 123891.62 lacs for the year ending on 31-MAR-2008. Net Profit / (Loss) of Rs. (5217.47) lacs for the year ending on 31-MAR-2009 against Rs. 18453.61 lacs for the year ending on 31-MAR-2008.29 Jun · Results
Consolidated Results for the year ended on 31-MAR-2009 as follows: Net Sales of Rs. 126002.49 lacs for year ending on 31-MAR-2009 against Rs. 130096.39 lacs for the year ending on 31-MAR-2008. Net Profit / (Loss) of Rs. (4898.99) lacs for the year ending on 31-MAR-2009 against Rs. 17533.99 lacs for the year ending on 31-MAR-2008.18 Jun · Board meeting
To: - (1) Approve the audited financial results of the Company for the financial year ended March 31, 2009. (2) Consider recommendation of dividend on equity capital for the financial year ended March 31, 2009.
May 2009
12 May · Legal
With reference to a news item appearing in a website attributing to the Company an announcement that the Company (Orchid) has received US FDA approval for its generic product Imipenem-Cilastatin 250 mg Injection. The Company has clarified that Orchid had made no such announcement and states that its ANDAs for the said injection in applicable dosage forms and strengths are under review by the US FDA.11 May · Business
Media release dated May 11, 2009 titled "Orchid receives Tentative US FDA nod for Sumatriptan Tablets". A copy of the media release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2009
24 Apr · Results
The company will be publishing the audited financial results for the year ended March 31, 2009 within a period of 3 months, i.e., on or before June 30, 200913 Apr · Updates
Company has so far purchased USD 37.8 million aggregate face value of 2012 bonds (US$ Zero Coupon Convertible Bonds due 2012) and USD 2.25 million aggregate face value of 2010 bonds (US$ Zero Coupon Convertible Bonds due on 2010) and the said bonds have been extinguished.9 Apr · Business
Press release dated April 09, 2009, titled "Orchid's facility conferred global recognition". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Apr · Change in Compliance officer
Mr. L Chandrasekar, Company Secretary and Compliance Officer has resigned, and relieved from the services of the Company with effect from the closing hours of March 31, 2009. Mrs. Bhoomijha Murali, General Manager - Legal & Secretarial has taken over as the Company Secretary from April 1, 2009. Mrs. Bhoomijha Murali, who has been designated as General Manager - Legal and Company Secretary, will also be the Compliance Officer of the Company
Mar 2009
31 Mar · Updates
Company has purchased USD 12.1 million aggregate face value of Bonds. The Company is in the process of extinguishing such Bonds. Further, the Company may also purchase from the markets and extinguish additional Bonds from time to time at its sole discretion.30 Mar · Updates
Company has purchased USD 25.7 million aggregate face value of Bonds and is in the process of extinguishing such Bonds. Further, the Company may also purchase from the markets and extinguish additional Bonds from time to time at its sole discretion.9 Mar · Results
Result of postal ballot conducted for the following matters: 1) Increase in Borrowing Limits, 2) Creation of Mortgages and Charges on the Company's properties against increased borrowing limits. The ordinary resolutions Nos.1 and 2, as set out in the notice dated January 28, 2009 were passed by the shareholders of the Company with requisite majority. The details of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements) For more details click here.5 Mar · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the quarter ended December 31,2008.A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2009
12 Feb · Meeting
In terms of the provisions of Section 192A of the Companies Act, 1956 read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2001, to seek the approval of members through Postal Ballot for passing the following Resolutions as ordinary resolutions; 1) Increase in Borrowing Limits, 2) Creation of Mortgages and Charges. The Board of Directors at their meeting held on January 28, 2009 has decided to seek the approval of the shareholders by way of postal ballot and for this purpose has appointed Mrs. S. Lalitha, Practicing Company Secretary, Chennai, as the Scrutinizer to receive and scrutinize the completed Ballot Papers from the members. Duly completed Postal Ballot should reach the scrutinizer on or before March 07, 2009. The Scrutinizer will submit her report to the Chairman of the Company after completion of the scrutiny and the results of postal ballot will be announced on March 07, 2009. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2009
28 Jan · Business
Press release dated January 28, 2009, titled "Orchid registers turnover of Rs.310 crore during Q3 FY09 Maintains operational profitability (PBT) at Rs.28 crore; Earnings for the quarter ended December 31, 2008 (Q3 FY09)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.28 Jan · Results
Standalone Results for the quarter ended on 31-DEC-2008 as follows: Net Sales of Rs. 29527.51 lacs for quarter ending on 31-DEC-2008 against Rs. 33268.9 lacs for the quarter ending on 31-DEC-2007. Net Profit / (Loss) of Rs. (630.62) lacs for the quarter ending on 31-DEC-2008 against Rs. 5411.73 lacs for the quarter ending on 31-DEC-2007.20 Jan · Board meeting
Meeting on 28 Jan 2009: “Unaudited Financial Results for the qtr ended Dec 31, 2008”16 Jan · Business
Press release dated January 16, 2009, titled "Orchid receives US FDA approval for Levetiracetam Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2008
4 Dec · Business
Media release dated December 04, 2008 titled "Orchid receives US FDA approval for Divalproex Sodium DR tablets". A copy of the media release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2008
14 Nov · Limited Review Report
Auditor's have conducted the limited review of the Un-audited financial results for the period ended September 30, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2008
30 Oct · Business
Press release dated October 30, 2008, titled "Orchid's revenue during Q2FY09 rises by 18.7% to Rs. 348.45 crore; Achieves Salient progress in the Generics and R & D Verticals". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Oct · Results
Standalone Results for the half year ended on 30-SEP-2008 as follows: Net Sales of Rs. 62169.14 lacs for half year ending on 30-SEP-2008 against Rs. 53332.62 lacs for the half year ending on 30-SEP-2007. Net Profit / (Loss) of Rs. (7230.64) lacs for the half year ending on 30-SEP-2008 against Rs. 11457.07 lacs for the half year ending on 30-SEP-2007.30 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 33914.02 lacs for quarter ending on 30-SEP-2008 against Rs. 29512.98 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. (4066.05) lacs for the quarter ending on 30-SEP-2008 against Rs. 6327.26 lacs for the quarter ending on 30-SEP-2007.24 Oct · Meeting
Proceedings of the Annual General Meeting of the Company held on September 29, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Oct · Board meeting
Meeting on 30 Oct 2008: “Unaudited financial results for qtr ended September 30, 2008”16 Oct · Business
Press release dated October 16, 2008, titled "Orchid receives US FDA approvals for three Cefuroxime Inj. ANDAs". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Oct · Management
Dr Anzaghi Piergiorgio, Director has resigned from the Board of Orchid Chemicals & Pharmaceuticals Limited with effect from October 3, 2008
Sep 2008
29 Sep · Business
Press release dated September 29, 2008, titled "Orchid & Merck & Co., Inc. collaborate to develop novel anti-infective drugs". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Sep · Management
Industrial Development Bank of India has withdrawn the nomination of Shri S Andi and instead appointed Shri S Jeyakumar, General Manager, Infrastructure Corporate Group, Industrial Development Bank of India Limited, Mumbai as its nominee on the Board of Orchid Chemicals & Pharmaceuticals Limited with effect from September 08, 2008
Aug 2008
29 Aug · Allotment of Equity Shares
Allotment Committee of the Board of Directors of the Company at their meeting held on August 29, 2008 have allotted 41,79,000 equity shares of Rs. 10 each at a price of Rs. 202.58 per share pursuant to conversion of warrants by the persons in Promotor/Promotor Group. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Aug · Meeting
Annual General Meeting of the Company is scheduled to be held on September 29, 2008. Further, the dates of closure of Register of Members for the purpose of Annual General Meeting and for payment of dividend has been fixed by the Board from September 20, 2008 to September 29, 2008 (both days inclusive).20 Aug · Limited Review Report
Auditor's have conducted the limited review of the Un-audited financial results (provisional) for the quarter ended June 30, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Aug · Allotment of shares
The Allotment Committee of the Board of Directors of Orchid Chemicals and Pharmaceuticals Limited at their meeting held on August 13, 2008 have allotted 385000 equity share of Rs. 10 each as per particulars given below: (1) 381000 equity shares of Rs. 10 each in favour of R. Sowmya at a price of Rs. 202.58 per share pursuant to conversion of warrants granted to Promoter/Promoter Group. These equity shares would be subject to lock-in till February 28, 2010. (2) 3000 equity shares of Rs. 10 each in favour R. Narayanan, Chairman, at a price of Rs. 200.44 per share under ESOP 1999 Scheme. (3) 1000 equity shares of Rs. 10 each in favour employees at a price of Rs. 193.25 per share under ESOP 2005 Scheme. The shares allotted under the ESOP scheme would be subject to a lock-in for a period of 1 year from the date of allotment. Consequent to this allotment, the paid-up capital of the Company has increased from Rs. 658,765,760 to Rs. 662,615,76014 Aug · Business
Press release dated August 13, 2008, titled "Orchid to develop Novel Anticoagulant Drug Candidate from Merck". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Aug · Business
Press release dated August 04, 2008, titled "Orchid receives EU approvals for Piperacillin Tazobactam injection". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2008
30 Jul · Business
Press release dated July 30, 2008, titled "Orchid's Q1 FY09 income grows 30%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 28765.92 lacs for quarter ending on 30-JUN-2008 against Rs. 23819.64 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. (3164.6) lacs for the quarter ending on 30-JUN-2008 against Rs. 5129.8 lacs for the quarter ending on 30-JUN-2007.30 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 30993.43 lacs for quarter ending on 30-JUN-2008 against Rs. 25176.97 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. (3384.8) lacs for the quarter ending on 30-JUN-2008 against Rs. 4858.94 lacs for the quarter ending on 30-JUN-2007.22 Jul · Board meeting
Meeting on 30 Jul 2008: “Unaudited Financial Results for the Qtr ended June 30, 2008”
Jun 2008
24 Jun · Business
Press release dated June 24, 2008, titled, "Orchid receives Canadian approval for Piperacillin Tazobactam injection". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2008
29 May · Allotment of Equity Shares
Allotment Committee of the Board of Directors of the Orchid Chemicals & Pharmaceuticals Limited at their meeting held on May 29, 2008 have allotted 16,375 equity share of Rs. 10 each as per particulars given below : 1) 16,175 equity shares of Rs. 10 each (16,150 equity shares at an adjusted price of Rs. 200.44 per share and 25 equity shares at a revised price of Rs. 193.25 per share) to the employees under ESOP 1999 Scheme and 2) 200 equity shares of Rs. 10 each at a price of Rs. 193.25 per share to the employees under ESOP 2005 Scheme. Further, out of the above allotment 6,000 equity shares of Rs.10/- each have been allotted to Shri. R. Narayanan, Director & Chairman under ORCHID-ESOP 1999 Scheme. The above equity shares will be locked in for a period of one year from the date of Allotment. Consequent to this allotment, the paid-up capital of the Company has increased from Rs. 658,602,010 to Rs. 658,765,760".29 May · Business
Press release dated May 29, 2008, titled "Orchid's FY08 turnover rises by 36% to Rs.1239 crore; Net profit records a growth of 91%; Board recommends dividend of 30%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.